查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092305

失眠藥物治療市場：全球市場預測（2026-2032）

Insomnia Pharmacological Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，失眠藥物治療市場將成長至 50.1 億美元，複合年成長率為 5.96%。

主要市場統計數據
基準年（2025 年） 33.4億美元
預計年份（2026年） 35.3億美元
預測年份（2032年） 50.1億美元
複合年成長率（） 5.96%

隨著臨床醫生、保險公司和監管機構在有效促進入睡和維持睡眠治療與安全性、次日功能、藥物依賴風險以及長期患者療效之間尋求平衡，失眠的藥物治療也在不斷發展。治療方案包括處方催眠藥、苯二氮平受體促效劑、褪黑素受體促效劑、Orexin受體拮抗劑、特定情況下使用的鎮靜抗憂鬱症以及經當地監管機構批准的區域性藥物。臨床指引繼續強調準確診斷、評估合併的精神和身體疾病、審查藥物管理以及將認知行為療法作為失眠的基礎干預措施，並在症狀具有臨床意義、持續存在或控制不佳時考慮藥物治療。睡眠障礙負擔日益加重、人口老化、輪班工作、數位化生活方式導致的睡眠模式紊亂，以及人們越來越認知到未經治療的失眠與生活品質下降、職場效率降低、事故風險增加和對醫療保健服務依賴性增強有關，這些因素都進一步推動了對循證失眠治療的需求。影響經營團隊優先事項的搜尋引擎最佳化（SEO）相關主題包括：失眠藥物、睡眠障礙治療、處方助眠藥、Orexin受體拮抗劑、慢性失眠管理、睡眠藥物治療、催眠藥和以患者為中心的睡眠醫學。

失眠治療領域的一次根本性改變。

失眠藥物治療領域正經歷著一場根本性的變革，其驅動力在於人們日益關注更安全的作用機制、更嚴格的處方標準以及個人化照護。由於人們擔心耐受性、依賴性、跌倒、認知功能障礙、呼吸系統合併症以及術後精神運動功能障礙等問題，傳統鎮靜劑和催眠藥的處方正在被重新評估，尤其是在老年患者和服用多種藥物的患者中。同時，Orexin路徑調節療法正日益受到臨床關注，因為它著眼於覺醒調節而非廣泛的中樞神經系統抑制，從而支持針對慢性失眠的差異化治療方法。監管機構和臨床學會越來越建議進行仔細的風險獲益評估、在適當情況下短期用藥、患者諮詢以及監測複雜的睡眠行為和殘留鎮靜作用。數位療法、基於遠端醫療的睡眠評估、穿戴式睡眠數據以及藥屋主導的藥物管理也在改變患者獲得治療和監測藥物依從性的途徑。這些變化正在將該領域從單純抑制症狀轉變為“精準睡眠護理”，它將藥物治療與行為干預、合併症管理和現實世界安全監測相結合。

人工智慧（AI）的累積影響

人工智慧 (AI) 正透過改進篩檢、臨床決策支援、藥物安全性分析以及基於真實世界數據的證據創建，開始影響失眠藥物治療。 AI 工具可以分析電子健康記錄、處方歷史、穿戴式裝置採集的睡眠模式以及患者報告的結局，從而幫助識別失眠表現型、檢測禁忌症、預警藥物交互作用並選擇合適的治療方案。在研究領域，機器學習可以加速藥物安全監測資料庫中的訊號檢測，識別治療反應的預測因子，並透過改進患者分層和終點測量來支持臨床試驗的設計。 AI 還透過整合數位睡眠日記、腕動計和用藥依從性檢驗來增強遠端監測，使臨床醫生能夠快速最佳化治療方案。然而，臨床有效性、透明度、隱私保護、減少偏差以及與處方標準的一致性對於其應用至關重要。人工智慧的整體影響並非取代臨床判斷，而是增強對更安全、更個人化、更實證的失眠藥物的管理。

縱覽全球失眠症治療領域的主要區域差異。

在亞太地區，失眠藥物治療受到大都會圈人口、高度工作生活平衡、日本、韓國、中國和澳洲人口老化以及基層醫療和專科醫療機構對睡眠障礙日益成長的認知等因素的影響。各地區的監管和報銷機制差異顯著，導致人們在獲取新型催眠藥物和繼續使用現有療法方面存在差異。在北美，基於指引的失眠管理在臨床實務中已廣泛應用，處方催眠藥供應充足，同時對受管制物質、藥物安全性和老年人處方的監測也更加嚴格。在拉丁美洲，公共和私人醫療保健體系的碎片化、專科醫生資源匱乏以及在精神健康和慢性病負擔日益加重的國家對價格合理的睡眠障礙治療的需求，都影響著人們獲得治療的模式。在歐洲，系統性的藥物安全監測、國家處方指南以及對非藥物第一線治療的重視依然存在，但針對持續性失眠的標靶藥物治療的需求仍然持續存在。在中東，由於生活方式的改變、代謝性疾病盛行率的上升以及私人醫療基礎設施的擴展，人們對睡眠障礙的認知正在提高。在整個非洲，失眠治療的普及程度仍然不均衡，但治療機會與基層醫療的加強、與精神衛生服務的合作、基本藥物的可及性以及睡眠障礙診斷準確性的提高密切相關，尤其是在受壓力、都市化和合併症影響的人群中。

基於群體的失眠藥物治療主要分析

在東協市場，醫療保健成熟度參差不齊，失眠藥物治療的普及程度都市化、職場壓力、私人藥房的可及性以及對精神衛生服務投入增加的影響。海灣合作理事會（GCC）國家的特點是專科醫療保健不斷擴展、數位醫療接受度高，以及對與肥胖、糖尿病、輪班工作和生活方式相關風​​險因素引起的睡眠障礙日益關注。在歐盟，統一的藥品安全標準與各國具體的報銷和處方規範並存，謹慎使用失眠藥物並將其與行為療法結合仍然至關重要。在金磚國家，儘管由於人口眾多、慢性病負擔加重以及醫療保健覆蓋範圍擴大，臨床需求顯著，但監管能力、經濟能力和新型睡眠藥物的可及性存在差異。在七國集團（G7）國家，臨床指引的普及率普遍較高，藥物安全監測基礎設施完善，先進療法廣泛應用，因此最佳化藥物治療、重複處方和真實世界臨床結果成為核心優先事項。北約成員國與北美和歐洲的先進醫療保健系統有很大的重疊，在這些國家，失眠治療策略與安全用藥越來越緊密地聯繫在一起，尤其是在軍事準備、退伍軍人健康、壓力相關的睡眠障礙和合併精神健康問題的人群中。

各國對失眠藥物治療的關鍵見解。

在美國，失眠治療系統高度發達，處方藥廣泛可及，臨床意識也較高，但人們仍然擔憂鎮靜劑的安全性、管制藥物的使用以及治療伴有焦慮、憂鬱症、疼痛和睡眠呼吸中止症等併發症的失眠問題。在加拿大，實證處方、公眾健康意識和謹慎用藥（尤其是在老年族群中）備受重視。在墨西哥和巴西，由於都市區壓力、心理健康負擔以及替代療法的普及，對睡眠障礙治療的需求不斷成長，但成本效益和專家的分佈仍然是重要的考慮因素。在英國，失眠的治療深受國家臨床指南、基層醫療把關以及對行為療法的重視的影響，行為療法或優先於藥物治療，或與藥物治療並行。在德國、法國、義大利和西班牙，成熟的法律規範體系、各國特有的處方規範和保險報銷機制，為謹慎選擇用於治療慢性失眠和短期睡眠障礙的催眠藥物提供了支持。在俄羅斯，與壓力相關的睡眠障礙和神經系統疾病診療路徑有需求，而各地區的醫療服務可近性水準會影響藥物治療的選擇。在中國和印度，由於人口規模、都市化、老化以及人們對睡眠健康意識的提高，存在大量未被滿足的需求，儘管不同地區的醫療服務可及性、診斷率和經濟負擔能力存在差異。日本的情況尤其重要，因為其人口老化、睡眠相關疾病盛行率高，並且對老年人用藥安全性高度關注。在澳大利亞，人們越來越重視基於指南的醫療保健、數位健康支援的廣泛應用以及對鎮靜催眠藥處方的嚴格監控。在韓國，先進的醫療保健服務、高工作壓力以及人們對睡眠醫學日益成長的認知，共同促成了對臨床差異化失眠治療的需求。

為行業領導者提供的實用建議

產業領導者應優先進行證據收集工作，以證明藥物在改善入睡、維持睡眠、提高日間功能、增強安全性以及改善患者自述生活品質（QOL）方面具有臨床意義。研發策略應著重於差異化的作用機制、低濫用風險、老年族群的良好安全性、以合併症為基礎的處方適用性。相關人員應加強真實世界證據（RWE）計畫、藥物警戒和上市後安全性監測，以解決殘留鎮靜、跌倒、認知功能障礙、複雜睡眠行為和藥物交互作用等問題。銷售和醫療團隊應開展符合臨床指南的教育，重點強調正確的診斷、患者選擇、治療持續時間、劑量調整策略以及與失眠認知行為療法相結合。藥物可近性策略應反映國家醫保報銷的實際情況、經濟限制以及基層醫療醫生、精神科醫生、神經科、老年科醫生、呼吸系統科醫生和藥劑師的作用。只有當數位化睡眠工具和人工智慧輔助技術經臨床驗證有效、能夠保護隱私並能提高藥物依從性、監測效果或改善個人化治療時，才應予以應用。此外，領導者還應增加對老年人、女性、輪班工作者、合併精神健康問題的患者以及其他在睡眠醫學研究中歷來代表性不足的群體的全面研究投入。

分析方法

本報告採用系統性的二手資料研究方法，利用經核實的公共領域權威資訊來源，包括監管公告、臨床實踐指南、同行評審的醫學文獻、藥物安全監測參考資料、公共衛生出版物以及國際公認的衛生政策研究途徑，檢驗而成。此分析方法強調對臨床證據、監管標準、治療指南和區域醫療保健可近性指標的數據進行檢驗。研究結果評估了其與失眠藥物治療的相關性，包括藥物類型、安全性考慮因素、處方實踐、患者群體、合併症模式以及不斷發展的數位健康應用。報告整合了區域、群體和國家層面的說明，以反映已記錄的醫療保健系統特徵、監管成熟度、人口統計因素和治療可及性趨勢，且未使用市場估算、預測、市場規模、市場佔有率或預測數據。本分析優先考慮可重複性、資訊來源可靠性、臨床相關性以及與目前實證睡眠醫學實踐的一致性。

結論

失眠藥物治療正朝著更具選擇性、更注重安全性和以患者為中心的方向發展。這一領域的發展趨勢體現在從廣泛鎮靜療法轉向基於機制的療法、與行為療法更緊密的結合以及真實世界安全性監測的普及。人工智慧和數位睡眠技術有望促進篩檢、藥物依從性追蹤和個人化處方改進，但其價值取決於臨床檢驗和負責任的管治。不同地區在藥物可及性、保險報銷、監管和臨床實踐方面的差異將繼續影響療法的應用。同時，人口老化、壓力水平高且睡眠醫學基礎設施完善的國家預計將繼續在創新和實證醫學方面發揮核心作用。對於行業領導者而言，最具吸引力的發展路徑是將差異化的藥理學與嚴謹的安全性數據、基於指南的教育、公平的藥物可及性計劃以及患者療效的可衡量改善相結合。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：人工智慧（AI）的累積影響（2026 年）

第7章：失眠藥物治療市場：依藥物類別分類

  • 苯二氮平類藥物
    • 艾司唑侖
    • 替馬西泮
    • 三唑侖
  • 褪黑素受體促效劑
    • Agomelatine
    • 褪黑素
    • 拉丁美洲爾修斯
  • 非苯二氮平類催眠藥
    • 依佐匹克隆
    • Zaleplon
    • Zolpidem
      • 緩釋製劑
      • 速釋製劑
  • Orexin受體拮抗劑
    • 倫博萊桑
    • 斯沃雷桑特
  • 鎮靜性抗憂鬱症
    • 多塞平
    • 特拉佐登

第8章：失眠藥物治療市場：依劑型分類

  • 膠囊
    • 硬明膠
    • 軟明膠
  • 口服懸浮液
  • 藥片
    • 緩釋劑型
    • 速釋劑型

第9章：失眠藥物治療市場：依睡眠障礙類型分類

  • 入睡困難 失眠
  • 睡眠維持障礙型失眠
  • 混合性失眠

第10章：失眠藥物治療市場：依通路分類

  • 醫院藥房
    • 私人的
    • 民眾
  • 網路藥房
    • 市場
    • 專業網路藥房
  • 零售藥房
    • 連鎖店
    • 獨立的

第11章 失眠藥物治療市場：依最終使用者分類

  • 居家醫療
    • 帶護理人員的老年住宅
    • 私人居家醫療
  • 醫院
    • 綜合醫院
    • 精神病院
  • 專科診所
    • 門診部
    • 睡眠障礙診所

第12章：失眠藥物治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：失眠藥物治療市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 失眠藥物治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）

第16章：公司簡介

  • Academics Pharmaceuticals Inc
  • Alembic Pharmaceuticals Ltd
  • Alkem Laboratories Ltd
  • Astellas Pharma Inc
  • Aurobindo Pharma Ltd
  • Avadel Pharmaceuticals plc
  • Bayer AG
  • Cipla Ltd
  • Currax Pharmaceuticals LLC
  • Dr Reddy's Laboratories Ltd
  • Eisai Co Ltd
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd
  • H Lundbeck A/S
  • Idorsia Ltd
  • Jazz Pharmaceuticals plc
  • Lupin Ltd
  • Mankind Pharma Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Procter & Gamble Health Ltd
  • Sanofi SA
  • Sumitomo Pharma Co Ltd
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • Viatris Inc
  • Zydus Lifesciences Ltd
Product Code: MRR-FB6C9E792FEB

The Insomnia Pharmacological Treatment Market is projected to grow by USD 5.01 billion at a CAGR of 5.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.34 billion
Estimated Year [2026] USD 3.53 billion
Forecast Year [2032] USD 5.01 billion
CAGR (%) 5.96%

Insomnia pharmacological treatment is evolving as clinicians, payers, and regulators balance the need for effective sleep initiation and sleep maintenance therapies with safety, next-day functioning, dependence risk, and long-term patient outcomes. The treatment landscape includes prescription hypnotics, benzodiazepine receptor agonists, melatonin receptor agonists, orexin receptor antagonists, sedating antidepressants used in selected cases, and regionally available agents supported by local regulatory pathways. Clinical guidance continues to emphasize accurate diagnosis, assessment of comorbid psychiatric and medical conditions, medication review, and the use of cognitive behavioral therapy for insomnia as a foundational intervention, with pharmacotherapy considered when symptoms are clinically significant, persistent, or inadequately controlled. Demand for evidence-based insomnia medication is reinforced by the high burden of sleep disorders, aging populations, shift work, digital lifestyle disruption, and the increasing recognition that untreated insomnia is associated with impaired quality of life, workplace productivity loss, accident risk, and greater healthcare utilization. SEO-relevant themes shaping executive priorities include insomnia drugs, sleep disorder treatment, prescription sleep aids, orexin receptor antagonists, chronic insomnia management, pharmacological sleep therapy, hypnotic medications, and patient-centered sleep medicine.

Transformative Shifts in the Insomnia Treatment Landscape

The insomnia pharmacological treatment landscape is undergoing transformative shifts driven by safer mechanism-based therapies, tighter prescribing expectations, and a stronger focus on individualized care. Traditional sedative-hypnotic prescribing is being reassessed due to concerns regarding tolerance, dependence, falls, cognitive effects, respiratory comorbidity, and next-day psychomotor impairment, particularly among older adults and patients with polypharmacy. At the same time, orexin pathway modulation has expanded clinical interest because it targets wakefulness regulation rather than broad central nervous system depression, supporting a differentiated approach to chronic insomnia therapy. Regulatory agencies and clinical societies increasingly encourage careful benefit-risk evaluation, short-duration use where appropriate, patient counseling, and monitoring for complex sleep behaviors and residual sedation. Digital therapeutics, telehealth-based sleep assessment, wearable sleep data, and pharmacy-led medication management are also changing treatment access and adherence monitoring. These shifts are moving the sector from symptom suppression toward precision sleep care, where pharmacological treatment is integrated with behavioral intervention, comorbidity management, and real-world safety surveillance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence insomnia pharmacological treatment through improved screening, clinical decision support, medication safety analytics, and real-world evidence generation. AI-enabled tools can analyze electronic health records, prescription histories, wearable-derived sleep patterns, and patient-reported outcomes to help identify insomnia phenotypes, detect contraindications, flag drug-drug interactions, and support appropriate therapy selection. In research settings, machine learning can accelerate signal detection in pharmacovigilance databases, identify predictors of treatment response, and support trial design by improving patient stratification and endpoint measurement. AI is also enhancing remote monitoring by connecting digital sleep diaries, actigraphy, and adherence data, enabling clinicians to refine treatment plans more quickly. However, adoption must be governed by clinical validation, transparency, privacy protection, bias mitigation, and alignment with prescribing standards. The cumulative impact of artificial intelligence is not the replacement of clinical judgment, but the strengthening of safer, more personalized, and evidence-driven insomnia medication management.

Key Regional Insights Across Global Insomnia Treatment

In Asia-Pacific, insomnia pharmacological treatment is shaped by large urban populations, high work intensity, aging demographics in Japan, South Korea, China, and Australia, and growing awareness of sleep disorders across primary care and specialty channels. Regulatory and reimbursement pathways differ widely, creating variation in access to newer hypnotic classes and continued use of established therapies. North America demonstrates strong clinical adoption of guideline-informed insomnia management, broad availability of prescription sleep medications, and heightened scrutiny of controlled substances, medication safety, and older-adult prescribing. In Latin America, access patterns are influenced by public and private healthcare fragmentation, specialist availability, and the need for affordable sleep disorder treatment in countries with rising mental health and chronic disease burdens. Europe is characterized by structured pharmacovigilance, national prescribing guidance, and emphasis on nonpharmacological first-line care, while still maintaining demand for targeted pharmacotherapy in persistent insomnia. The Middle East is seeing increasing recognition of sleep disorders alongside lifestyle changes, metabolic disease prevalence, and expanding private healthcare infrastructure. Across Africa, insomnia treatment access remains uneven, with opportunities tied to primary care strengthening, mental health integration, essential medicine availability, and better diagnosis of sleep disorders in populations affected by stress, urbanization, and comorbid disease.

Key Group Insights for Insomnia Pharmacological Treatment

ASEAN markets reflect diverse healthcare maturity, with insomnia pharmacological treatment adoption influenced by urbanization, workplace stress, private pharmacy access, and growing investment in mental health services across major economies. The GCC is marked by expanding specialty care, high digital health readiness, and increasing attention to sleep disorders associated with obesity, diabetes, shift work, and lifestyle-related risk factors. Within the European Union, harmonized medicine safety expectations coexist with country-specific reimbursement and prescribing practices, supporting careful use of insomnia drugs and ongoing preference for behavioral treatment integration. BRICS countries present substantial clinical need due to large populations, rising chronic disease burden, and expanding healthcare access, while also showing variability in regulatory capacity, affordability, and availability of newer sleep medications. G7 countries generally show higher clinical guideline penetration, stronger pharmacovigilance infrastructure, and broader availability of advanced therapies, making medication optimization, deprescribing, and real-world outcomes central priorities. NATO member countries overlap significantly with advanced healthcare systems in North America and Europe, where insomnia treatment strategies are increasingly linked to military readiness, veteran health, stress-related sleep disturbance, and safe prescribing in populations with mental health comorbidities.

Key Country Insights in Insomnia Pharmacological Treatment

The United States has a highly developed insomnia treatment environment with broad prescription availability, strong direct clinical awareness, and ongoing concern regarding sedative safety, controlled-substance use, and treatment of insomnia comorbid with anxiety, depression, pain, and sleep apnea. Canada emphasizes evidence-based prescribing, public health awareness, and cautious medication use, particularly among older adults. Mexico and Brazil show growing demand for sleep disorder treatment as urban stress, mental health burden, and private healthcare access expand, though affordability and specialist distribution remain important considerations. In the United Kingdom, insomnia management is strongly influenced by national clinical guidance, primary care gatekeeping, and emphasis on behavioral interventions before or alongside pharmacotherapy. Germany, France, Italy, and Spain combine mature regulatory oversight with country-specific prescribing traditions and reimbursement approaches, supporting careful selection of hypnotic medications for chronic insomnia and short-term sleep disturbance. Russia presents demand linked to stress-related sleep disorders and neurological care pathways, with local access dynamics shaping pharmacological choices. China and India carry large unmet clinical needs due to population scale, urbanization, aging, and increasing recognition of sleep health, while access, diagnosis rates, and affordability vary across regions. Japan has significant relevance due to its aging population, high sleep complaint prevalence, and strong attention to medication safety in older adults. Australia reflects guideline-driven care, increasing use of digital health support, and careful monitoring of sedative-hypnotic prescribing. South Korea combines advanced healthcare access, high work-related stress exposure, and growing sleep medicine awareness, supporting demand for clinically differentiated insomnia therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that demonstrates clinically meaningful improvements in sleep onset, sleep maintenance, next-day functioning, safety, and patient-reported quality of life. Development strategies should focus on differentiated mechanisms, lower abuse potential, favorable older-adult safety profiles, and compatibility with comorbidity-driven prescribing. Stakeholders should strengthen real-world evidence programs, pharmacovigilance, and post-authorization safety monitoring to address residual sedation, falls, cognitive effects, complex sleep behaviors, and drug-drug interactions. Commercial and medical teams should align education with clinical guidelines, emphasizing appropriate diagnosis, patient selection, duration of therapy, tapering strategies, and integration with cognitive behavioral therapy for insomnia. Access strategies should reflect country-level reimbursement realities, affordability constraints, and the role of primary care physicians, psychiatrists, neurologists, geriatricians, pulmonologists, and pharmacists. Digital sleep tools and AI-enabled support should be deployed only where clinically validated, privacy-protective, and capable of improving adherence, monitoring, or treatment personalization. Leaders should also invest in inclusive research across older adults, women, shift workers, patients with psychiatric comorbidity, and populations historically underrepresented in sleep medicine studies.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified public-domain and authoritative sources, including regulatory agency communications, clinical practice guidelines, peer-reviewed medical literature, pharmacovigilance references, public health publications, and internationally recognized healthcare policy resources. The methodology emphasizes data triangulation across clinical evidence, regulatory standards, treatment guidelines, and regional healthcare access indicators. Insights were assessed for relevance to insomnia pharmacological treatment, including medication classes, safety considerations, prescribing practices, patient populations, comorbidity patterns, and evolving digital health applications. Regional, group, and country-level narratives were synthesized to reflect documented healthcare system characteristics, regulatory maturity, demographic drivers, and treatment access dynamics without using market estimation, market sizing, market share, or forecasting. The analysis prioritizes reproducibility, source credibility, clinical validity, and consistency with current evidence-based sleep medicine practices.

Conclusion

Insomnia pharmacological treatment is entering a more selective, safety-conscious, and patient-centered phase. The sector is being shaped by the shift from broad sedative approaches toward mechanism-informed therapies, stronger integration with behavioral care, and wider use of real-world safety monitoring. Artificial intelligence and digital sleep technologies can improve screening, adherence tracking, and individualized prescribing, but their value depends on clinical validation and responsible governance. Regional differences in access, reimbursement, regulation, and clinical practice will continue to influence therapy adoption, while countries with aging populations, high stress exposure, and strong sleep medicine infrastructure are likely to remain central to innovation and evidence generation. For industry leaders, the most defensible path forward is to combine differentiated pharmacology with rigorous safety data, guideline-aligned education, equitable access planning, and measurable improvements in patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Insomnia Pharmacological Treatment Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Benzodiazepines
    • 7.2.1. Estazolam
    • 7.2.2. Temazepam
    • 7.2.3. Triazolam
  • 7.3. Melatonin Receptor Agonists
    • 7.3.1. Agomelatine
    • 7.3.2. Melatonin
    • 7.3.3. Ramelteon
  • 7.4. Non Benzodiazepine Hypnotics
    • 7.4.1. Eszopiclone
    • 7.4.2. Zaleplon
    • 7.4.3. Zolpidem
      • 7.4.3.1. Extended Release
      • 7.4.3.2. Immediate Release
  • 7.5. Orexin Receptor Antagonists
    • 7.5.1. Lemborexant
    • 7.5.2. Suvorexant
  • 7.6. Sedating Antidepressants
    • 7.6.1. Doxepin
    • 7.6.2. Trazodone

8. Insomnia Pharmacological Treatment Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Capsules
    • 8.2.1. Hard Gelatin
    • 8.2.2. Soft Gelatin
  • 8.3. Oral Suspension
  • 8.4. Tablets
    • 8.4.1. Controlled Release
    • 8.4.2. Immediate Release

9. Insomnia Pharmacological Treatment Market, by Sleep Disorder Type

  • 9.1. Introduction
  • 9.2. Sleep Onset Insomnia
  • 9.3. Sleep Maintenance Insomnia
  • 9.4. Mixed Insomnia

10. Insomnia Pharmacological Treatment Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
    • 10.2.1. Private
    • 10.2.2. Public
  • 10.3. Online Pharmacy
    • 10.3.1. Marketplaces
    • 10.3.2. Specialty Online Pharmacies
  • 10.4. Retail Pharmacy
    • 10.4.1. Chain
    • 10.4.2. Independent

11. Insomnia Pharmacological Treatment Market, by End User

  • 11.1. Introduction
  • 11.2. Homecare Settings
    • 11.2.1. Assisted Living
    • 11.2.2. Private Homecare
  • 11.3. Hospitals
    • 11.3.1. General Hospitals
    • 11.3.2. Psychiatric Hospitals
  • 11.4. Specialty Clinics
    • 11.4.1. Outpatient Clinics
    • 11.4.2. Sleep Disorder Clinics

12. Insomnia Pharmacological Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Insomnia Pharmacological Treatment Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Insomnia Pharmacological Treatment Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Academics Pharmaceuticals Inc
  • 16.2. Alembic Pharmaceuticals Ltd
  • 16.3. Alkem Laboratories Ltd
  • 16.4. Astellas Pharma Inc
  • 16.5. Aurobindo Pharma Ltd
  • 16.6. Avadel Pharmaceuticals plc
  • 16.7. Bayer AG
  • 16.8. Cipla Ltd
  • 16.9. Currax Pharmaceuticals LLC
  • 16.10. Dr Reddy's Laboratories Ltd
  • 16.11. Eisai Co Ltd
  • 16.12. GlaxoSmithKline plc
  • 16.13. Glenmark Pharmaceuticals Ltd
  • 16.14. H Lundbeck A/S
  • 16.15. Idorsia Ltd
  • 16.16. Jazz Pharmaceuticals plc
  • 16.17. Lupin Ltd
  • 16.18. Mankind Pharma Ltd
  • 16.19. Merck & Co Inc
  • 16.20. Novartis AG
  • 16.21. Pfizer Inc
  • 16.22. Procter & Gamble Health Ltd
  • 16.23. Sanofi SA
  • 16.24. Sumitomo Pharma Co Ltd
  • 16.25. Sun Pharmaceutical Industries Ltd
  • 16.26. Takeda Pharmaceutical Company Limited
  • 16.27. Teva Pharmaceutical Industries Ltd
  • 16.28. Torrent Pharmaceuticals Ltd
  • 16.29. Viatris Inc
  • 16.30. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BENZODIAZEPINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BENZODIAZEPINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BENZODIAZEPINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ESTAZOLAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ESTAZOLAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ESTAZOLAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TEMAZEPAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TEMAZEPAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TEMAZEPAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRIAZOLAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRIAZOLAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRIAZOLAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MELATONIN RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MELATONIN RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MELATONIN RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AGOMELATINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AGOMELATINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AGOMELATINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MELATONIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MELATONIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MELATONIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RAMELTEON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RAMELTEON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RAMELTEON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON BENZODIAZEPINE HYPNOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ESZOPICLONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ESZOPICLONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ESZOPICLONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ZALEPLON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ZALEPLON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ZALEPLON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ZOLPIDEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ZOLPIDEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ZOLPIDEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EXTENDED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EXTENDED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EXTENDED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OREXIN RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OREXIN RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OREXIN RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LEMBOREXANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LEMBOREXANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LEMBOREXANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUVOREXANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUVOREXANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SUVOREXANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEDATING ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SEDATING ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEDATING ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DOXEPIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DOXEPIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DOXEPIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRAZODONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRAZODONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRAZODONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HARD GELATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HARD GELATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HARD GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SOFT GELATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SOFT GELATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SOFT GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SLEEP ONSET INSOMNIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SLEEP ONSET INSOMNIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SLEEP ONSET INSOMNIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SLEEP MAINTENANCE INSOMNIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SLEEP MAINTENANCE INSOMNIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SLEEP MAINTENANCE INSOMNIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MIXED INSOMNIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MIXED INSOMNIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MIXED INSOMNIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MARKETPLACES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MARKETPLACES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MARKETPLACES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SPECIALTY ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SPECIALTY ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SPECIALTY ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CHAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CHAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INDEPENDENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INDEPENDENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INDEPENDENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ASSISTED LIVING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ASSISTED LIVING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ASSISTED LIVING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PRIVATE HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PRIVATE HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRIVATE HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PSYCHIATRIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PSYCHIATRIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PSYCHIATRIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL SLEEP DISORDER CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL SLEEP DISORDER CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL SLEEP DISORDER CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 277. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 279. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 280. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 282. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 283. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 284. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 285. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 288. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 289. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 296. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 297. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 300. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 301. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 302. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 303. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 304. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 305. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 308. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 309. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 310. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 312. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 313. G7 INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY NON BENZODIAZEPINE HYPNOTICS, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ZOLPIDEM, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SEDATING ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SLEEP DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)

TABLE 33